Search

Your search keyword '"Drozdz, J"' showing total 300 results

Search Constraints

Start Over You searched for: Author "Drozdz, J" Remove constraint Author: "Drozdz, J"
300 results on '"Drozdz, J"'

Search Results

1. Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry

2. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

4. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

5. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

6. Impact of renal impairment on atrial fibrillation

8. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe

9. Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry

10. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation:a report from ESC-EHRA EORP-AF Long-Term General Registry

11. Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry

15. Aortic Wall Velocity

17. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

18. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

19. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

20. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

21. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry

22. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

25. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry

26. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial

27. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

28. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

30. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

36. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure

37. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry

38. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry

39. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

41. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

42. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

43. [PP.24.06] CARDIAC PHENOTYPE BASED ON ANGIOGRAPHIC SUBTYPES AND VASCULAR INVOLVEMENT IN PATIENTS WITH FIBROMUSCULAR DYSPLASIA –ARCADIA-POL STUDY

44. P4389Relation of the heart rate reduction during hospitalization and the outcome of heart failure patients with sinus rhythm: results from the Polish part of the ESC-HF-Pilot and ESC-HF-Long Term Registrie

45. P5281Comparison of long-term outcomes of torasemide vs furosemide in heart failure patients. results from Heart Failure Registries of the European Society of Cardiology

46. P4899Do beta-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry

47. P4398Heart failure with Mid-Range ejection fraction - clinical characteristics and in-hospital outcomes. Insights into novel enigma based on the results from the ESC-HF Registries

48. P2454Prognostic value of different risk scores in heart failure

50. P5821Ischemic versus dilated cardiomyopathy - differences in clinical characteristics and prognosis depending on heart failure etiology

Catalog

Books, media, physical & digital resources